Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by alleyesonmeon Feb 13, 2022 2:40pm
276 Views
Post# 34424603

CBD, cannibal market, outlook USA.

CBD, cannibal market, outlook USA.just in the USA CBD sales were 4.6 Billion in 2020 and expected to hit 20 Billion by 2025 estimated by Forbes. Although Labs doesn't have sales in the US it's only a matter of time..similar growth globally is anticipated. Previous tolling business has died and we are emerging from the ashes though not at a pace most are accepting. Bottom line..global CBD oil sales is expected to grow 28% CAGR conservatively...If a fund is presently divesting they will gravely regret...BUY TIME...added more Thursday morning at .19....(I know...lol)....if share price doesn't recover soon takeover is inevitable...what big player wouldn't want an extraction facility in North America, and Australia to service Europe with DEL and GMP certs....Big money is ruthless...sell 2 million shares to buy 3 after looking retail...this bad behavior happens often...HOLD EM CLOSE...
<< Previous
Bullboard Posts
Next >>